Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of ka...

Full description

Bibliographic Details
Main Authors: Malin S. Nilsson, Alexander Hallner, Mats Brune, Staffan Nilsson, Fredrik B. Thorén, Anna Martner, Kristoffer Hellstrand
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
acute myeloid leukemia
histamine dihydrochloride
il-2
immunotherapy
relapse prevention
normal karyotype
Online Access:http://dx.doi.org/10.1080/21645515.2019.1636598

Internet

http://dx.doi.org/10.1080/21645515.2019.1636598

Similar Items